Agmatine enhances cannabinoid action in the hot-plate assay of thermal nociception

Pharmacology Biochemistry and Behavior

Volumn 93, Issue 4, 2009, Pages 426-432

  Aggarwal, Saniya ^a   Shavalian, Behnam ^a   Kim, Esther ^a   Rawls, Scott M ^a,b  

^a Temple University Health Sciences Center   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

Adrenergic receptor; Agmatine; Anandamide; Antinociception; Cannabinoid; CB1 receptor; CP55,940; Idazoxan; Imidazoline site; WIN 55212 2; Yohimbine

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AGMATINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR AGONIST; IDAZOXAN; IMIDAZOLINE; RIMONABANT; YOHIMBINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; HOT PLATE TEST; IMMUNOREACTIVITY; IN VIVO STUDY; LATENT PERIOD; MALE; NERVE CELL; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; REGRESSION ANALYSIS;

ADRENERGIC ALPHA-ANTAGONISTS; AGMATINE; ANIMALS; BENZOXAZINES; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HOT TEMPERATURE; IDAZOXAN; IMIDAZOLINE RECEPTORS; MALE; MORPHOLINES; NAPHTHALENES; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTOR, CANNABINOID, CB1; RECEPTORS, ADRENERGIC, ALPHA-2; YOHIMBINE;

EID: 67849086671     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2009.06.004     Document Type: Article

References (66)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., et al. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37 (1994) 1889-1893
2. Aricioglu F., and Regunathan S. Agmatine attenuates stress- and lipopolysaccharide-induced fever in rats. Physiol Behav 85 (2005) 370-375
3. Aricioglu-Kartal F., and Uzbay I.T. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats. Life Sci 61 (1997) 1775-1781
4. Auguet M., Viossat I., Marin J.G., and Chabrier P.E. Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn J Pharmacol 69 (1995) 285-287
5. Barinaga M. Neurobiology. How cannabinoids work in the brain. Science 291 (2001) 2530-2531
6. Bicher H.I., and Mechoulam R. Pharmacological effects of two active constituents of marihuana. Arch Int Pharmacodyn Ther 172 (1968) 24-31
7. Compton D.R., Gold L.H., Ward S.J., Balster R.L., and Martin B.R. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 263 (1992) 1118-1126
8. De Vry J., Jentzsch K.R., Kuhl E., and Eckel G. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15 (2004) 1-12
9. Deutsch D.G., and Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46 (1993) 791-796
10. Dewey W.L., Harris L.S., and Kennedy J.S. Some pharmacological and toxicological effects of 1-trans-8 and 1-trans-9-tetrahydrocannabinol in laboratory rodents. Arch Int Pharmacodyn Ther 196 (1972) 133-145
11. Eglen R.M., Hudson A.L., Kendall D.A., Nutt D.J., Morgan N.G., Wilson V.G., et al. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol Sci 19 (1998) 381-390
12. Fairbanks C.A., Schreiber K.L., Brewer K.L., Yu C.G., Stone L.S., Kitto K.F., et al. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci USA 97 (2000) 10584-10589
13. Feng Y., Halaris A.E., and Piletz J.E. Determination of agmatine in brain and plasma using high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 691 (1997) 277-286
14. Feng Y., LeBlanc M.H., and Regunathan S. Agmatine reduces extracellular glutamate during pentylenetetrazole-induced seizures in rat brain: a potential mechanism for the anticonvulsive effects. Neurosci Lett 390 (2005) 129-133
15. Fox A., and Bevan S. Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin Investig Drugs 14 (2005) 695-703
16. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., et al. The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92 (2001) 91-100
17. Gilad G.M., Salame K., Rabey J.M., and Gilad V.H. Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci 58 (1996) PL41-PL46
18. Head G.A., and Mayorov D.N. Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc Hematol Agents Med Chem 4 (2006) 17-32
19. Iversen L., and Chapman V. Cannabinoids: a real prospect for pain relief?. Curr Opin Pharmacol 2 (2002) 50-55
20. Kalra S.P., Pearson E., Sahu A., and Kalra P.S. Agmatine, a novel hypothalamic amine, stimulates pituitary luteinizing hormone release in vivo and hypothalamic luteinizing hormone-releasing hormone release in vitro. Neurosci Lett 194 (1995) 165-168
21. Kolesnikov Y., Jain S., and Pasternak G.W. Modulation of opioid analgesia by agmatine. Eur J Pharmacol 296 (1996) 17-22
22. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 (1999) 401-404
23. Lever I.J., and Rice A.S. Cannabinoids and pain. Handb Exp Pharmacol 177 (2007) 265-306
24. Li G., Regunathan S., Barrow C.J., Eshraghi J., Cooper R., and Reis D.J. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 263 (1994) 966-969
25. Li J., Li X., Pei G., and Qin B.Y. Effects of agmatine on tolerance to and substance dependence on morphine in mice. Zhongguo Yao Li Xue Bao 20 (1999) 232-238
26. Li Y.F., Gong Z.H., Cao J.B., Wang H.L., Luo Z.P., and Li J. Antidepressant-like effect of agmatine and its possible mechanism. Eur J Pharmacol 469 (2003) 81-88
27. Liang Y.C., Huang C.C., and Hsu K.S. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacology 53 (2007) 169-177
28. Loring R.H. Agmatine acts as an antagonist of neuronal nicotinic receptors. Br J Pharmacol 99 (1990) 207-211
29. Martin B.R. Structural requirements for cannabinoid-induced antinociceptive activity in mice. Life Sci 36 (1985) 1523-1530
30. Martin B.R., and Lichtman A.H. Cannabinoid transmission and pain perception. Neurobiol Dis 5 (1998) 447-461
31. Meng I.D., Manning B.H., Martin W.J., and Fields H.L. An analgesia circuit activated by cannabinoids. Nature 395 (1998) 381-383
32. 3H]-idazoxan binding sites in human cardiovascular tissues. Br J Pharmacol 122 (1997) 43-50
33. Molderings G.J., Likungu J., and Göthert M. Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. Naunyn Schmiedebergs Arch Pharmacol 360 (1999) 157-164
34. Monhemius R., Azami J., Green D.L., and Roberts M.H. CB1 receptor mediated analgesia from the nucleus reticularis gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Res 908 (2001) 67-74
35. Morgan N.G., and Chan S.L. Imidazoline binding sites in the endocrine pancreas: can they fulfill their potential as targets for the development of new insulin secretagogues?. Curr Pharm Des 7 (2001) 1413-1431
36. Nguyen H.O., Goracke-Postle C.J., Kaminski L.L., Overland A.C., Morgan A.D., and Fairbanks C.A. Neuropharmacokinetic and dynamic studies of agmatine (decarboxylated arginine). Ann N Y Acad Sci 1009 (2003) 82-105
37. Novelli G.P., Peduto V.A., Bertol E., Mari F., and Pieraccioli E. Analgesic interaction between nitrous oxide and delta-9-tetrahydrocannabinol in the rat. Br J Anaesth 55 (1983) 997-1000
38. Onal A., Delen Y., Ulker S., and Soykan N. Agmatine attenuates neuropathic pain in rats: possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellum. Life Sci 73 (2003) 413-428
39. Palazzo E., Marabese I., de Novellis V., Oliva P., Rossi F., Berrino L., et al. Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology 40 (2001) 319-326
40. Pertwee R.G. Cannabinoid receptors and pain. Prog Neurobiol 63 (2001) 569-611
41. Pettit D.A., Harrison M.P., Olson J.M., Spencer R.F., and Cabral G.A. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res 51 (1998) 391-402
42. Piletz J.E., Chikkala D.N., and Ernsberger P. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenoceptors. J Pharmacol Exp Ther 272 (1995) 581-587
43. Raasch W., Regunathan S., Li G., and Reis D.J. Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sci 56 (1995) 2319-2330
44. Raasch W., Schäfer U., Qadri F., and Dominiak P. Agmatine, an endogenous ligand at imidazoline binding sites, does not antagonize the clonidine-mediated blood pressure reaction. Br J Pharmacol 135 (2002) 663-672
45. Rawls S.M., Tallarida R.J., and Zisk J. Agmatine and a cannabinoid agonist, WIN 55212-2, interact to produce a hypothermic synergy. Eur J Pharmacol 553 (2006) 89-98
46. Rawls S.M., Amin M., and Zisk J. Agmatine blocks morphine-evoked hyperthermia in rats. Brain Res 1147 (2007) 89-94
47. Regunathan S., Feinstein D.L., Raasch W., and Reis D. Agmatine (decarboxylated arginine) is synthesized and stored in astrocytes. Neuroreport 6 (1995) 1897-1900
48. Regunathan S. Agmatine: biological role and therapeutic potentials in morphine analgesia and dependence. AAPS J 8 (2006) E479-484
49. Reis D.J., and Regunathan S. Is agmatine a novel neurotransmitter in brain?. Trends Pharmacol Sci 21 (2000) 187-193
50. Reis D.J., Yang X.C., and Milner T.A. Agmatine containing axon terminals in rat hippocampus form synapses on pyramidal cells. Neurosci Lett 250 (1998) 185-188
51. Roberts J.C., Grocholski B.M., Kitto K.F., and Fairbanks C.A. Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse. J Pharmacol Exp Ther 314 (2005) 1226-1233
52. Ruggiero D.A., Regunathan S., Wang H., Milner T.A., and Reis D.J. Immunocytochemical localization of an imidazoline receptor protein in the central nervous system. Brain Res 780 (1998) 270-293
53. Sastre M., Regunathan S., Galea E., and Reis D.J. Agmatinase activity in rat brain: a metabolic pathway for the degradation of agmatine. J Neurochem 67 (1996) 1761-1765
54. Schäfer U., Raasch W., Qadri F., Chun J., and Dominiak P. Effects of agmatine on the cardiovascular system of spontaneously hypertensive rats. Ann N Y Acad Sci 881 (1999) 97-101
55. Spina E., Trovati A., Parolaro D., and Giagnoni G. A role of nitric oxide in WIN 55,212-2 tolerance in mice. Eur J Pharmacol 343 (1998) 157-163
56. Su R.B., Li J., Gao K., Pei G., and Qin B.Y. Influence of idazoxan on analgesia, tolerance, and physical dependence of morphine in mice and rats in vivo. Acta Pharmacol Sin 21 (2000) 1011-1015
57. Su R.B., Li J., and Qin B.Y. A biphasic opioid function modulator: agmatine. Acta Pharmacol Sin 24 (2003) 631-636
58. Sun M.K., Regunathan S., and Reis D.J. Cardiovascular responses to agmatine, a clonidine-displacing substance, in anesthetized rat. Clin Exp Hypertens 17 (1995) 115-128
59. Tallarida R.J. Drug synergism: its detection and applications. J Pharmacol Exp Ther 298 (2001) 865-872
60. Thorat S.N., and Bhargava H.N. Effects of NMDA receptor blockade and nitric oxide synthase inhibition on the acute and chronic actions of delta 9-tetrahydrocannabinol in mice. Brain Res 667 (1994) 77-82
61. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., and Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998) 393-411
62. Welch S.P., and Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 262 (1992) 10-18
63. Welch S.P., Thomas C., and Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 272 (1995) 310-321
64. Wu N., Su R.B., and Li J. Agmatine and imidazoline receptors: their role in opioid analgesia, tolerance and dependence. Cell Mol Neurobiol 28 (2007) 629-641
65. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., and Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96 (1999) 5780-5785
66. Zomkowski A.D., Santos A.R., and Rodrigues A.L. Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci Lett 381 (2005) 279-283